Dual-Agonist Incretin Therapy Outshines GLP-1 Agonist in Broad Cardiorenal Outcomes

Cleveland Clinic·Mar 30

This story is reported by Cleveland Clinic. Read what other outlets are saying below, then open the original report for full details.